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OBJECTIVES: The current analysis evaluates the long-term impacts on household
productivity and social participation of CZP 400mg Q4W combination and mono-
therapy over 5 years. METHODS: In this open-label extension (OLE) (NCT00160693)
patients (pts) originally enrolled in FAST4WARD (NCT00548834) or study 014
(NCT00544154) received CZP 400 mg Q4W for 24 wks. Pts who completed or with-
drew on/after Wk12 in either study were eligible and were permitted to take
DMARDs in OLE. Household productivity and social participation were assessed
through the RA-specific Work Productivity Survey (WPS-RA); results are reported
up to Wk268 (5.2yrs). The analyzed population consisted of (1) Wk 24 CZP com-
pleters from FAST4WARD (N75) or 014 (N96) who entered the OLE (all pts group)
and (2) FAST4WARD CZP completers who entered OLE and did not receive MTX/
DMARDs (N48) (monotherapy subgroup).RESULTS: In both populations analyzed,
a rapid reduction in the number of days of household work days missed per month
was seen from feeder study baseline (BL, 7.4 and 11.1 mean days respectively) over
24wks of the feeder studies to OLE entry (3.5 and 4.1 mean days respectively) and
continued to decline over time, up to Week 268 (1.2 and 1.4 mean days respec-
tively). Increased participation in family/social/leisure activities was reported in
both populations, with a decrease in the number of days missed per month from
feeder study baseline (4.4 and 6.2 mean days, respectively), to entry to OLE, at a
mean of 1.3 and 1.1 days respectively for monotherapy pts; improvements contin-
ued over the 5 years to 0.4 and 0.2 days on average in the 2 populations respectively.
CONCLUSIONS: CZP treatment, in combination with MTX/DMARDs or as mono-
therapy, rapidly decreased the number of household work or social/family/leisure
days missed per month. These improvements were maintained up to 5 years with
open-label CZP following 24 wks double-blind CZP therapy.
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CONSUMPTION IN HUNGARIAN HOSPITALS
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OBJECTIVES: Due to the global economic crisis, most of the actions of the Hungar-
ian government are focused on cost reductions, including in the health care sector.
According to the ownership structure’s changes (i.e., the state becoming the
owner), the most important thing is to create a well-monitored and centralized
hospital system. In addition to these changes, the government seeks to centralize
the procurement of pharmaceuticals and medical equipment at state-owned
hospitals.METHODS:We have prepared literature review and interviews with high
level hospital and political leaders to find how can we strengthen the regulation of
drug consumption at hospitals, which is at this time without strict controls.
RESULTS: Due to the specific objectives of the HunDRG system, which are focused
more on monitoring the number of DRG cases than tracking resources, there are no
incentives for hospitals to maintain strict inventories of their drugs. Except for
biological drugs, which use an itemized financing system, there is no pressure by
the government to monitor the medical costs at the unit level; as such, only hos-
pital data exists. Based on IMS data in 2011, the total hospital sector was valued at
approximately 100 billion HUF. Most of the hospitals do not have adequate com-
puter systems to monitor the patient-level data. CONCLUSIONS: In conclusion, the
so called unit-dose system could be a good solution to measure the drug consump-
tion at the patient level and to improve drug security (trial system). To sum up, it is
very important to gain more data regarding the Hungarian hospital system to be
able to create a sustainable, transparent, highly-regulated, and centralized public
health care system.
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OBJECTIVES: In France, the reimbursement decisions and price negotiations for
new drugs are highly influenced by the National Authority of Health (HAS) recom-
mendations communicated in the formal health technology assessment (HTA).
This study aimed to analyse past criterions and consider future possible require-
ments influencing future submissions.METHODS:A convenient internet literature
review was conducted to identify categories for value drivers in the evaluation of
the incremental medical benefit (ASMR) for a new product. An analysis of five
biological products reviewed 2006-2012 for rheumatology disorders was conducted
using these criterions. Based on the findings, exploratory interviews with two ex-
HAS members were performed to gain insight into future potential evidence
requirements. RESULTS: From the literature review three categories of evidence
were developed. Firstly ‘socioeconomics’, to include the French payers’ perspective
of burden and cost of illness. The second category was ‘clinical evidence’, evaluat-
ing the added therapeutic value for a target population, the clinical efficacy and
safety. The third category was ‘real world data’, to establish effectiveness and
long-term safety post-launch. From the analysis it was demonstrated that only
products targeting patients with an insufficient response to anti-TNFs were rec-
ommended a high -level II- ASMR. Only 2 of 14 phase III studies used an active
comparator in Phase III superiority studies. Open label extension studies were
commonly used to provide post-launch data. Findings of the interviews suggested
that in the future superiority verses current standard of care in France for a clear
target population would be the expectation for an ASMR  IV from the HAS.
CONCLUSIONS: These findings emphasise the need to integrate payer evidence
requirements into the clinical development strategy early on. Effort should be
directed towards the identification of a clear target population demonstrating su-
perior efficacy to standard of care.
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UTILIZATION OF PAIN MEDICATIONS AMONG OSTEOARTHRITIS PATIENTS
WHO INITIATED DULOXETINE AND STANDARD OF CARE FOR PAIN
MANAGEMENT
Peng X1, Chen SY2, Wu N2, Yu X2, Andrews JS1, Novick D3
1Eli Lilly and Company, Indianapolis, IN, USA, 2United BioSource Corporation, Lexington, MA,
USA, 3Eli Lilly and Company, Windlesham, Surrey, UK
OBJECTIVES: To compare utilization of pain medications between osteoarthritis
(OA) patients initiating duloxetine and standard of care (SOC) after duloxetine’s
approval for OA. METHODS: Pharmacy and medical claims from SDI Health were
analyzed for adult osteoarthritis patients (ICD-9-CM: 715.xx) initiating duloxetine
or SOC (celecoxib, gabapentin, pregabalin, or venlafaxine) between 11/2010 and
4/2011. Treatment initiation was defined as no pill coverage over 90 days prior, and
first dispense date was defined as index date. Included patients did not use opioids
in 90 days before index date. Propensity score matching was used to select patients
with similar baseline demographic and clinical characteristics for duloxetine and
SOC cohorts. Compliance to index medication was assessed via medication pos-
session ratio (MPR), proportion of days covered (PDC) and proportion discontinued
(a 60-day gap in medication access) for 6 months after index date. Opioids use
after index date was assessed and regression models were estimated to compare
opioid use between cohorts. RESULTS: A total of 1102 patients initiated duloxetine
and 4,302 patients initiated SOC. After matching, 1,021 patients were selected for
duloxetine (mean age: 63 years; female: 79%) and SOC (mean age: 64 years; female:
79%) cohorts, respectively. Duloxetine cohort had significantly higher MPR (0.80 vs.
0.74) and PDC (0.52 vs. 0.43), and were less likely to discontinue initiated medication
(55% vs. 68%) than SOC cohort (all p0.001). Duloxetine cohort was less likely to use
opioids after index date (49% vs. 56%, p0.002), and had fewer days on opioids
(mean: 18 vs. 22, p0.004) than SOC cohort. After adjusting for baseline character-
istics, duloxetine cohort initiated opioids later than SOC cohort (Hazard ratio: 0.85,
95% confidence interval: 0.75-0.97) and had fewer days on opioids (beta: -4.0,
p0.011). CONCLUSIONS: Patients with OA initiating duloxetine were associated
with better compliance to initiated medication and less likely to use opioids than
those initiating SOC.
PMS71
UTILIZATION OF DULOXETINE AND CELECOXIB IN OSTEOARTHRITIS PATIENTS
Andrews JS1, Wu N2, Chen SY2, Yu X2, Peng X1, Novick D3
1Eli Lilly and Company, Indianapolis, IN, USA, 2United BioSource Corporation, Lexington, MA,
USA, 3Eli Lilly and Company, Windlesham, Surrey, UK
OBJECTIVES: To describe utilization patterns of duloxetine and celecoxib and sub-
sequent opioid use among patients with osteoarthritis (OA) after duloxetine’s ap-
proval for OA. METHODS: Pharmacy and medical claims from SDI Health were
analyzed for adult osteoarthritis patients (ICD-9-CM: 715.xx) who initiated dulox-
etine or celecoxib between 11/2010 and 4/2011. Initiation was defined as no pill
coverage in 90 days prior. Included patients had continuous enrollment in 6
months before and after the initiation and did not use opioid in 90 days before the
initiation. Propensity score matching was used to select patients with similar de-
mographic and clinical characteristics for duloxetine and celecoxib cohorts. Com-
pliance to index medication was assessed via medication possession ratio (MPR),
proportion of days covered (PDC), and proportion discontinued (no access for 60
days). Initiating dose and opioid use after index date was assessed. Cox propor-
tional hazard model was estimated to compare time to first opioid use. RESULTS:A
total of 1360 patients initiated duloxetine and 1,408 patients initiated celecoxib.
After matching, 784 patients were selected for duloxetine (mean age: 66, female:
78%) and celecoxib (mean age: 66; female: 76%) cohorts, respectively. 92.5% of
duloxetine cohort started on 60mg/day, the recommended dose, and 72.8% of
celecoxib cohort started on 200mg/day. Duloxetine cohort had higher MPR and
PDC and a lower proportion of discontinuation than celecoxib cohort (MPR: 0.81 vs.
0.70; PDC: 0.51 vs. 0.35; discontinuation: 57% vs. 78%. all p0.001). A lower propor-
tion of duloxetine cohort used opioids after index date (48.6% vs. 68.5%, p0.001),
and started on opioid later than celecoxib cohort (mean: 132 vs. 107, p0.001). After
controlling for baseline characteristics, duloxetine cohort initiated opioids later
than celecoxib cohort (Hazard ratio: 0.67, 95% confidence interval: 0.58-0.76).
CONCLUSIONS: OA patients initiating duloxetine had better compliance and a
lower likelihood of opioid utilization than those initiating celecoxib.
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OBJECTIVES: Opioids are commonly used to manage chronic pain, including os-
teoarthritis (OA). Duloxetine is approved for OA therapy, but no study has assessed
changes in utilization of opioid therapy following its approval. This study assessed
adherence and the change of opioid use between OA patients who initiated dulox-
etine versus celecoxib. METHODS: Employing administrative claims data, OA pa-
tients aged 18 years who initiated duloxetine or celecoxib between November
2010 and April 2011, and used opioids in 6 months before the initiation, were
identified. Initiation was defined as no access to the same medication over the prior
90 days, and the first dispense date of index medication was denoted as the “index
date”. Patients with80% days covered by index medication during follow-up were
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considered adherent users. Bootstrap methods stratified by propensity score were
used to compare adherence and the changes in opioid use 6 months before and
after index date, and regression models were applied to identify factors associated
with change in opioid use. RESULTS: A total of 3033 duloxetine patients and 1065
celecoxib patients were identified. Duloxetine cohort were more likely to adhere to
the treatment than celecoxib cohort (27.4% vs. 15.0%, p0.01). Both cohorts had
significant increases (pre- to post-index) in days on opioids (duloxetine: 3.6, p0.01;
celecoxib: 11.2, p0.01) and morphine equivalent units (duloxetine: 588.8, p0.01;
celecoxib: 587.7, p0.01), whereas only celecoxib cohort had significant increase in
the number of opioid prescriptions (duloxetine: 0.06, p0.44; celecoxib: 0.65,
p0.01). After adjusting for baseline characteristics using bootstrap method, cele-
coxib cohort had significantly greater increase in days on opioids (18.2, p0.01),
morphine equivalent units (1,144, p0.01) and number of opioid prescriptions
(1.24, p0.01) than duloxetine cohort. CONCLUSIONS: Patients who initiated du-
loxetine were more likely to adhere to the initiated treatment than celecoxib initi-
ators, and had significantly less increase in opioid use after initiation.
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OBJECTIVES: In health outcomes research, where researchers from many disci-
plines interact frequently, a tool to communicate treatment patterns clearly and
effectively through graphical means is a necessity. Using data visualization tech-
niques, we aimed to present treatment patterns of rheumatoid arthritis (RA)
patients. METHODS: This study used the Veterans Health Administration (VHA)
Medical SAS® Dataset for patients age 18 with at least two diagnoses for RA 60
days apart during the 1-year baseline period. Patients who initiated therapy with
tumor necrosis factor (TNF) and non-TNF agents were identified. We examined
treatment patterns (switch to another TNF, to a non-TNF, discontinuation) for 2
years after TNF biologic initiation. We created a data visualization tool to represent
changes in treatment patterns after the first and second switches. RESULTS:A total
of 3,205 RA patients initiated therapy with a TNF medication. 12.45% of these pa-
tients switched to another TNF, while 1.65% switched to a non-TNF, 42.12% discon-
tinued therapy and 43.78% continued initial therapy. Among patients who
switched to another TNF, 58.40% continued the switched therapy, 30.08% discon-
tinued, 6.77% switched to another TNF, and 4.76% switched to a non-TNF. Of pa-
tients who first switched to a non-TNF, 67.92% discontinued. The percentages of
those who switched to another anti-TNF and to a non-TNF were both 3.77%. A total
of 412 RA patients initiated therapy with a non-TNF, of which 1.21% switched to
another non-TNF, 3.16% switched to a TNF, 90.29% discontinued, and 5.34% con-
tinued initial therapy. Among those who switched to another TNF, 7.69% switched
to a non-TNF, 30.77% continued, and 46.15% discontinued. All patients who first
switched to another non-TNF discontinued treatment during the second switch
period. CONCLUSIONS: When analyzing subsequent years and switches, treat-
ment patterns can be difficult to capture. Data visualization tools help present
complicated flows effectively for a diverse research audience.
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OBJECTIVES: In recent years, methodologies used in outcomes research have ad-
vanced. In a field where many researchers from a variety of disciplines (e.g., clini-
cians, epidemiologists, economists, statisticians) interact frequently, a tool to com-
municate information clearly and effectively through graphical means has become
necessary. We present treatment patterns among Veterans Health Administration
(VHA) patients diagnosed with ankylosing spondylitis (AS) using data visualization
techniques.METHODS:Using the VHA Medical SAS® Dataset, we selected patients
18 with at least one AS diagnosis. We identified patients who initiated therapy
with tumor necrosis factor (TNF) and non-TNF agents. For 2 years after the initia-
tion date, we analyzed switches to another TNF, a non-TNF, and continuation and
discontinuation treatment patterns. Using a processing language, we created a
data visualization tool to demonstrate changes in treatment patterns after the first
and second switches. RESULTS: A total of 1,021 AS patients initiated therapy with
TNF. 13.52% of these patients switched to another TNF, 0.20% switched to a non-
TNF, 49.56% discontinued therapy and 36.73% continued their initial therapy.
Among patients who switched to another TNF, 60.87% remained on the switched
therapy, while 31.16% discontinued therapy, 7.97% switched to another TNF, and
no patients switched to a non-TNF. 81.82% of patients who made a second switch
to a TNF medication remained on it, while 9.09% discontinued. A total of 84 AS
patients initiated therapy with a non-TNF. 4.76% of these patients switched to a
TNF, 1.19% switched to another non-TNF, 93.61% discontinued therapy and no
patients continued. Of those patients whose first switch was to a TNF, 50% contin-
ued while the remaining 50% discontinued. No second switches were made.
CONCLUSIONS: Treatment patterns can be difficult to present, especially when
analyzing several years of data and various drug switches. Data visualization tools
can help present these complicated flows effectively to researchers.
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ADHERENCE WITH NON-BIOLOGIC DMARDS IN COMBINATION WITH ANTI-TNF
THERAPY
Engel-nitz NM1, Ogale S2, Kulakodlu M1
1OptumInsight, Eden Prairie, MN, USA, 2Genentech, South San Francsico, CA, USA
OBJECTIVES: Studies have shown better response for anti-TNFs (aTNF) in combi-
nation with non-biologic DMARDs (nbDMARD), than as monotherapies in rheuma-
toid arthritis (RA) (Nixon 2007). Non-adherence to nbDMARDs prescribed in com-
bination with aTNFs may reduce the benefit of aTNFs. We examined the use of
aTNF monotherapy and adherence with nbDMARDs in RA patients receiving com-
bination aTNFnbDMARDs. METHODS: We conducted claims analysis of adult RA
patients in a US managed care plan, initiating aTNF agents between Jan’06-Dec’10.
aTNF initiators were classified as ‘biologic-naïve’ or ‘previously-exposed’ based on
prior biologic use, and followed until discontinuation of that aTNF or disenroll-
ment. Proportion of patients receiving aTNF as monotherapy (no nbDMARD during
aTNF follow-up) was determined. In combination therapy patients (received nbD-
MARD during aTNF follow-up), adherence to nbDMARDs was defined as the per-
cent of days that patients received any nbDMARD while they were receiving the
aTNF agent. RESULTS: Of 7,074 biologic-naïve RA patients initiating an aTNF, 27%
received it as monotherapy and 73% in combination with nbDMARDs. Of 2,690
aTNF patients previously exposed to biologics, 31% received monotherapy and 69%
in combination with nbDMARDs. Only 42% of patients receiving aTNF mono-
therapy vs. 89% of combination therapy patients had filled a nbDMARD prescrip-
tion during the 6 months prior to initiating the aTNF. Among biologic-naïve com-
bination therapy patients, 52% of patients adhered with nbDMARD therapy less
than 80% of the time while receiving aTNFs; 32% of the patients had less than 60%
adherence. Results were similar for aTNF patients previously exposed to biologics.
CONCLUSIONS:We found that up to 31% of patients receiving an aTNF agent for RA
received it as monotherapy, and a substantial proportion of those receiving com-
bination therapy had less than 60% adherence with nbDMARDs. Some of these
patients may have sub-optimal outcomes, as suggested by evidence that RA pa-
tients receiving aTNFs in combination with nbDMARDs have better response.
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OBJECTIVES: Rheumatoid Arthritis (RA) patients’ access to biologics differs among
European countries. We aimed to explore the views of Portuguese health care
stakeholders on key barriers limiting patients’ access to biologics, areas of inter-
vention to overcome the identified barriers (leverage points) and corresponding
key initiatives. METHODS: A qualitative research consisting of semi-structured
face-to-face interviews with key stakeholders in RA framework. Thirty six people
from eight groups of stakeholders were interviewed: rural and urban general prac-
titioners (GPs), rheumatologists, hospital managers, hospital pharmacists, budget
holders, representatives from rheumatology society and RA patient association.
Interviews were conducted between May and June 2011. Conventional content
analysis with research triangulation was used. RESULTS: The identified key barri-
ers were related with accessibility to primary health care, difficulties in RA diag-
nosis among GPs, inefficient referral to secondary health care, controlled process of
biologics prescription and medical apprehensiveness about biologics safety. The
leverage points included the improvement of national epidemiologic and clinical
knowledge on RA, promotion of disease understanding among patients and GPs,
promotion of biologics benefits among budget holders and overall spreading of the
current treatment guidelines. In order to address the leverage points, the following
key initiatives were selected: optimization of RA national registry; dissemination of
rheumatic symptoms knowledge among patients; increased interaction between
rheumatologists and GPs through clinical sessions; awareness regarding success-
ful case reports about biologics; broader utilization of disease diagnosis and mon-
itoring tool (e.g.DAS28) and implementation of hospital–based research to collect
real-world data. CONCLUSIONS: Most of the key barriers limiting access to biolog-
ics in RA in Portugal are upstream to rheumatology practice. Our findings suggest
that actions should be focused at the primary care level to improve referral to
rheumatologists. In addition, the collection of real-world data seems essential to
characterize RA population, to improve the disease management and to increase
the compliance with current treatment guidelines.
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OBJECTIVES: To compare health care utilization between duloxetine initiators and
pregabalin initiators among fibromyalgia patients in a real-world setting.
METHODS: A retrospective cohort study was conducted based on a US national
commercial health claims database (2006-2009). Fibromyalgia patients who initi-
ated duloxetine or pregabalin in 2008, age 18 to 64, and maintained continuous
health insurance coverage one year before and one year after initiation were as-
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